Freedonia predicts 7% per year rise in US enzyme demand to 2010
A recent report from US research firm Freedonia predicts that domestic enzyme demand will grow 6.9% annually through 2010, based on strong gains in key markets such as animal feed, biocatalysts, pharmaceuticals and starch processing. Pharmaceuticals will remain the largest market and one of the fastest growing.The most rapid growth will occur in animal feed additives, led by phytase.
This study analyzes the $1.6 billion US enzyme industry and presents historical demand data and figures for 1995, 2000 and 2005 and forecasts to 2010 and 2015 by product and by market. The study also considers market environment factors, evaluates company market share and profiles 36 major players including Novozymes, Danisco, Allergan, Genzyme, Genentech, Archer-Daniels-Midland and Roche.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze